The diagnosis of multiple sclerosis (MS) has rested on the twin tenets of typical disseminated disease activity (disseminated in time (DIT) and disseminated in space (DIS)) and no better explanation since Schumacher et al. 1 The important changes to the criteria are enumerated below (see also Table 1 and 2):
1. CSF OCBs may substitute for a second clinical event or MRI finding for DIT. That is, with a typical CIS and fulfilment of clinical or MRI criteria for DIS, the demonstration of CSF OCBs (two or more immunoglobulin G (IgG) bands detected in the CSF and not in the paired serum sample, using agarose gel electrophoresis with isoelectric focusing and immunoblotting or immunofixation for IgG) with other CSF parameters typical of MS, allows a diagnosis of MS to be made. This represents a major departure from the requirement of a discrete event and/or focal MRI lesion to be identified for DIT and on which the diagnosis of MS has rested since 1965 1 and an elevation of the role of CSF OCBs in diagnosis. Nevertheless, the change has a significant evidence base 7, 8 and, as is commented upon in the 2017 Revision, 5 is reminiscent of the laboratory-supported definite MS categories in the 1983 Poser Criteria. 9 2. The pivotal role of MRI in the early diagnosis of MS and the recent evidence of improved sensitivity without loss of specificity 6 led to (a) symptomatic as well as asymptomatic MRI lesions to be considered in the determination of DIS or DIT 10, 11 (the one exception being lesions in the optic nerve in a patient presenting with optic neuritis where there is insufficient evidence for these to be utilized in the diagnosis at present), and (b) cortical and juxtacortical lesions are now given the same weighting to fulfil the MRI criteria for DIS. 12 The four areas for typical lesions (periventricular, cortical/juxtacortical, infratentorial and spinal cord) are essentially maintained
and not yet extended to include the optic nerve, despite having been proposed as the fifth area in the recommendations of the 2016 MAGNIMS report. 4. Phenotype designation (relapsing-remitting, primary progressive or secondary progressive) commences once the diagnosis of MS is established. It is recommended that the course 13 (active or not, progressive or not, based on the prior year's history) be combined with the phenotype designation to better represent temporal disease activity.
There are additional important considerations made by the Panel, but not included in the revised criteria. As with all refinements of diagnostic criteria, there exists a fine line between achieving certainty of diagnosis or not which is based largely on the interpretation of one or more of the elements required for diagnosis. Implicit in this version as in earlier ones is the caution required in the application of the criteria and also as explicitly formulated by the Panel in the 2017 McDonald Criteria that if there is doubt, especially if the presentation is atypical, allow time and further evaluation to provide the certainty. Although there is an art to clinical diagnosis, it must always be guided by adherence to the evidence-based criteria if patient and clinician are to benefit. It is to be hoped, if not expected, that the 2017 McDonald Criteria and their correct application will serve us well until the next revision.
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